Yesterday it was reported that the VP Patent and General Counsel of Omeros Corp (OMER – Research Report), Marcia Kelbon, exercised options to buy 10,000 OMER shares at $6.05 a share, for a total transaction value of $60.5K.
This recent transaction increases Marcia Kelbon’s holding in the company by 4.98% to a total of $3.56 million.
Based on Omeros Corp’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $21.78 million and GAAP net loss of $24.35 million. In comparison, last year the company earned revenue of $1.59 million and had a GAAP net loss of $30.05 million. Currently, Omeros Corp has an average volume of 426.6K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $27.75, reflecting a 64.3% upside. Three different firms, including Cantor Fitzgerald and Maxim Group, currently also have a Buy rating on the stock.
Marcia Kelbon’s trades have generated a 50.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.